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ABSTRACT
We performed exome-wide association studies to identify genetic variants that 
influence systolic or diastolic blood pressure or confer susceptibility to hypertension 
in Japanese. The exome-wide association studies were performed with the use of 
Illumina HumanExome-12 DNA Analysis BeadChip or Infinium Exome-24 BeadChip 
arrays and with 14,678 subjects, including 8215 individuals with hypertension and 
6463 controls. The relation of genotypes of 41,843 single nucleotide polymorphisms 
to systolic or diastolic blood pressure was examined by linear regression analysis. 
After Bonferroni’s correction, 44 and eight polymorphisms were significantly (P < 
1.19 × 10–6) associated with systolic or diastolic blood pressure, respectively, with six 
polymorphisms (rs12229654, rs671, rs11066015, rs2074356, rs3782886, rs11066280) 
being associated with both systolic and diastolic blood pressure. Examination of the 
relation of allele frequencies to hypertension with Fisher’s exact test revealed that 
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100 of the 41,843 single nucleotide polymorphisms were significantly (P < 1.19 × 10–
6) associated with hypertension. Subsequent multivariable logistic regression analysis 
with adjustment for age and sex showed that five polymorphisms (rs150854849, 
rs202069030, rs139012426, rs12229654, rs76974938) were significantly (P < 1.25 
× 10–4) associated with hypertension. The polymorphism rs12229654 was thus 
associated with both systolic and diastolic blood pressure and with hypertension. 
Six polymorphisms (rs12229654 at 12q24.1, rs671 of ALDH2, rs11066015 of ACAD10, 
rs2074356 and rs11066280 of HECTD4, and rs3782886 of BRAP) were found to be 
associated with both systolic and diastolic blood pressure, with those at 12q24.1 or 
in ACAD10 or BRAP being novel determinants of blood pressure in Japanese.
INTRODUCTION
Hypertension is a major risk factor for coronary 
artery disease and stroke [1], with a heritability estimated 
to be ~30% [2]. Genome-wide association studies 
(GWASs) have implicated various loci and genes in 
predisposition to hypertension in populations of European 
[3–6] or African [7] ancestry as well as in Chinese [8] 
and Japanese [9] individuals. A recent trans-ancestry 
GWAS in individuals of European and East or South 
Asian ancestry identified 12 loci associated with blood 
pressure (BP) [10]. Most of the genetic variants identified 
in these studies have a minor allele frequency (MAF) of 
≥5% and a small individual effect size. Given that these 
common variants explain only a fraction of the heritability 
of hypertension, low-frequency (0.5% ≤ MAF < 5%) or 
rare (MAF < 0.5%) variants with larger effect sizes likely 
contribute to the genetic architecture of this condition 
[11].
We have now performed exome-wide association 
studies (EWASs) with the use of exome array–based 
genotyping methods to identify single nucleotide 
polymorphisms (SNPs)—in particular, low-frequency or 
rare coding variants with moderate to large effect sizes—
that confer susceptibility to elevated BP or hypertension 
in Japanese. We applied Illumina human exome arrays 
that provide coverage of functional SNPs in entire exons 
including low-frequency and rare variants.
RESULTS
EWASs for systolic and diastolic BP
We examined the relation of genotypes for 41,843 
SNPs that passed quality control to systolic or diastolic 
BP by linear regression analysis. Manhattan plots of 
the EWASs for systolic and diastolic BP are shown in 
Supplementary Figure 1. After Bonferroni’s correction, 
44 or eight SNPs were significantly (P < 1.19 × 10–6) 
associated with systolic (Table 1) or diastolic (Table 2) 
BP, respectively. Among these SNPs, six polymorphisms 
(rs12229654 at 12q24.1, rs671 of ALDH2, rs11066015 
of ACAD10, rs2074356 and rs11066280 of HECTD4, 
rs3782886 of BRAP) were significantly associated with 
both systolic and diastolic BP.
EWAS for hypertension
We next performed an EWAS for hypertension. 
The characteristics of the subjects enrolled in the study 
are shown in Table 3. Age, the frequency of men, body 
mass index, and the prevalence of diabetes mellitus, 
dyslipidemia, chronic kidney disease, and hyperuricemia 
were greater, whereas the prevalence of smoking was 
lower, in subjects with hypertension than in controls. We 
examined the relation of allele frequencies of 41,843 SNPs 
to hypertension with Fisher’s exact test. A Manhattan plot 
of the EWAS for hypertension is shown in Supplementary 
Figure 1. After Bonferroni’s correction, 100 SNPs were 
significantly (P < 1.19 × 10–6) associated with hypertension 
(Supplementary Table 1). The genotype distributions 
of these SNPs were in Hardy-Weinberg equilibrium (P 
≥ 0.001) among both subjects with hypertension and 
controls (Supplementary Table 2).
Multivariable logistic regression analysis of the 
relation of SNPs to hypertension
The relation of the 100 SNPs identified in the EWAS 
for hypertension to this condition was further examined by 
multivariable logistic regression analysis with adjustment 
for age and sex (Supplementary Table 3). Nine SNPs were 
related (P < 0.01 in any one genetic model) to hypertension 
(Table 4), and five of these SNPs (rs150854849 of 
DCLRE1C, rs202069030 of DUS2, rs139012426 of 
LOC100505549, rs12229654 at 12q24.1, rs76974938 of 
C21orf59) were significantly (P < 1.25 × 10–4) associated 
with this condition. The minor T allele of rs150854849 
was a risk factor for hypertension, whereas the minor 
C (rs202069030), C (rs139012426), G (rs12229654), 
and T (rs76974938) alleles of the other four SNPs were 
protective against this condition. The rs12229654 SNP at 
12q24.1 was significantly associated with both systolic 
and diastolic BP as well as with hypertension.
Relation of SNPs identified in the present study 
to systolic or diastolic BP
We next examined the relation of genotypes for 
the 50 SNPs isolated in the present study to systolic or 
diastolic BP by one-way analysis of variance (ANOVA) 
(Table 5). The SNP rs12229654, which was identified 
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Table 1: The 44 single nucleotide polymorphisms (SNPs) significantly (P < 1.19 × 10–6) associated with systolic blood 
pressure by the exome-wide association study
Gene dbSNP
Nucleotide 
(amino acid) 
substitutiona
Chromosome: 
position MAF (%) P (genotype)
MUC17 rs78010183 A/T (T1305S) 7: 101035329 1.8 3.86 × 10–32
OR4F6 rs141569282 G/A (A117T) 15: 101806068 1.7 1.10 × 10–27
COL6A5 rs200982668 G/A (E2501K) 3: 130470894 1.3 2.45 × 10–22
MARCH1 rs61734696 G/T (Q137K) 4: 164197303 1.2 3.48 × 10–22
PLCB2 rs200787930 C/T (E1095K) 15: 40289298 1.2 6.54 × 10–22
MOB3C rs139537100 C/T (R24Q) 1: 46615006 1.2 2.54 × 10–21
VPS33B rs199921354 C/T (R80Q) 15: 91013841 1.2 4.06 × 10–21
CXCL8 rs188378669 G/T (E31*) 4: 73741568 1.2 1.40 × 10–20
COL6A3 rs146092501 C/T (E1386K) 2: 237371861 1.2 2.45 × 10–20
ZNF77 rs146879198 G/A (R340*) 19: 2934109 1.2 2.70 × 10–20
TMOD4 rs115287176 G/A (R277W) 1: 151170961 1.2 5.08 × 10–20
ADGRL3 rs192210727 G/T (R580I) 4: 61909615 1.3 1.20 × 10–19
PRAMEF12 rs199576535 G/A (V341I) 1: 12777168 1.0 5.70 × 10–16
PTCH2 rs147284320 C/T (V503I) 1: 44828589 2.0 4.36 × 10–14
IGSF9B rs201459911 G/A (A1115V) 11: 133920381 0.7 6.77 × 10–14
rs12229654 T/G 12: 110976657 22.5 2.04 × 10–11
ALDH2 rs671 G/A (E504K) 12: 111803962 27.6 3.97 × 10–11
ACAD10 rs11066015 G/A 12: 111730205 27.5 8.38 × 10–11
HECTD4 rs2074356 C/T 12: 112207597 25.4 4.48 × 10–10
BRAP rs3782886 A/G 12: 111672685 29.3 2.82 × 10–9
HECTD4 rs11066280 T/A 12: 112379979 29.0 3.38 × 10–9
RNF213 rs199976159 G/A (G222S) 17: 80288217 0.3 3.98 × 10–9
rs2523638 G/A 6: 31376496 43.1 1.12 × 10–8
AS3MT rs11191454 A/G 10: 102900247 26.8 2.39 × 10–8
rs12182351 T/C 6: 32233930 29.8 2.42 × 10–8
CNNM2 rs12413409 G/A 10: 102959339 26.4 3.24 × 10–8
NPFFR2 rs144936999 G/C (A332P) 4: 72147237 0.2 4.16 × 10–8
rs404890 G/T 6: 32231090 30.5 4.94 × 10–8
CCHCR1 rs130075 C/T (R102Q) 6: 31154725 13.2 5.07 × 10–8
NT5C2 rs11191580 T/C 10: 103146454 26.3 6.68 × 10–8
HLA-B rs1058026 T/G 6: 31353908 33.4 9.03 × 10–8
CNNM2 rs11191548 T/C 10: 103086421 26.3 9.31 × 10–8
C6orf15 rs2270191 C/T (V5M) 6: 31112543 12.4 1.79 × 10–7
CDSN rs117951780 C/T (S453N) 6: 31116257 12.3 2.45 × 10–7
C6orf15 rs2270190 T/C 6: 31112809 12.9 2.96 × 10–7
(Continued )
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in the EWASs for systolic and diastolic BP and 
hypertension, was significantly (P < 0.0005) associated 
with both systolic and diastolic BP. The SNPs rs671, 
rs11066015, rs2074356, rs3782886, and rs11066280 
identified in the EWASs for systolic and diastolic BP 
were also significantly associated with both systolic 
and diastolic BP. In addition, rs141569282 of OR4F6, 
rs2523638 at 6p21.3, and rs10849915 of CCDC63 
identified in the EWAS of systolic BP were significantly 
associated with both systolic and diastolic BP. The 
SNPs rs150854849, rs202069030, rs139012426, and 
rs76974938 identified in the EWAS for hypertension 
were not significantly associated with either systolic 
or diastolic BP, probably because of the effect of 
antihypertensive treatment.
Linkage disequilibrium and haplotype analysis
Given that the six SNPs (rs12229654, rs671, 
rs11066015, rs2074356, rs3782886, rs11066280) found 
to be associated with both systolic and diastolic BP are 
all located at chromosomal region 12q24.12-q24.13, 
we examined linkage disequilibrium among these 
polymorphisms as well as the relation of their 
haplotypes to hypertension. The six SNPs were all in 
strong linkage disequilibrium (Supplementary Table 
4). Haplotype analysis revealed that the haplotypes T 
(rs12229654)-G (rs671)-G (rs11066015)-C (rs2074356)-A 
(rs3782886)-T (rs11066280) and G (rs12229654)-A 
(rs671)-A (rs11066015)-T (rs2074356)-G (rs3782886)-A 
(rs11066280) were significantly (P < 9.62 × 10–4) 
Gene dbSNP
Nucleotide 
(amino acid) 
substitutiona
Chromosome: 
position MAF (%) P (genotype)
CYP17A1 rs17115100 G/T 10: 102831636 33.5 3.44 × 10–7
rs72655343 C/A 11: 1104741 0.1 4.24 × 10–7
PSORS1C1 rs1063646 C/T (P133L) 6: 31139871 12.9 5.26 × 10–7
CCHCR1 rs9263739 C/T 6: 31143579 12.9 5.26 × 10–7
CYP17A1 rs1004467 T/C 10: 102834750 32.4 5.63 × 10–7
CAT rs139421991 G/A (R320Q) 11: 34456720 0.3 6.74 × 10–7
PSORS1C2 rs7757012 T/C 6: 31140785 13.0 8.23 × 10–7
RNF39 rs142979264 C/T 6: 30075223 11.8 9.58 × 10–7
CCDC63 rs10849915 T/C 12: 110895818 23.6 1.18 × 10–6
The relation of genotypes of SNPs to systolic blood pressure was analyzed with a linear regression model. aMajor allele/
minor allele. MAF, minor allele frequency.
Table 2: The eight single nucleotide polymorphisms (SNPs) significantly (P < 1.19 × 10–6) associated with diastolic 
blood pressure by the exome-wide association study
Gene dbSNP
Nucleotide 
(amino acid) 
substitutiona
Chromosome: 
position MAF (%) P (genotype)
ALDH2 rs671 G/A (E504K) 12: 111803962 27.6 2.18 × 10–15
ACAD10 rs11066015 G/A 12: 111730205 27.5 4.08 × 10–15
BRAP rs3782886 A/G 12: 111672685 29.3 2.46 × 10–14
HECTD4 rs11066280 T/A 12: 112379979 29.0 8.38 × 10–14
HECTD4 rs2074356 C/T 12: 112207597 25.4 2.41 × 10–13
rs12229654 T/G 12: 110976657 22.5 2.16 × 10–12
ATXN2 rs7969300 T/C (N248S) 12: 111555908 38.8 2.62 × 10–8
NAA25 rs12231744 C/T (R876K) 12: 112039251 35.1 6.76 × 10–7
The relation of genotypes of SNPs to diastolic blood pressure was analyzed with a linear regression model. aMajor allele/
minor allele. MAF, minor allele frequency.
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associated with hypertension, with the former haplotype 
representing a risk factor for and the latter being protective 
against this condition (Supplementary Table 5).
Relation of chromosomal loci, genes, and SNPs 
identified in the present study to phenotypes 
examined in previous GWASs
Finally, we examined the relation of the 50 
SNPs of 44 genes or chromosomal loci identified in 
the present study to phenotypes previously probed in 
GWASs that are available in a public database [GWAS 
Catalog (National Human Genome Research Institute 
and European Bioinformatics Institute), http://www.
ebi.ac.uk/gwas] (Supplementary Table 6). ALDH2 [10], 
HECTD4 [10], AS3MT [12], CNNM2 [6, 10, 13, 14], 
NT5C2 [10], and CYP17A1 [4, 10] were previously 
identified as loci associated with BP in previous 
GWASs.
Table 3: Characteristics of the 14,678 study subjects
Characteristic Hypertension Controls P
No. of subjects 8215 6463
Age (years) 67.2 ± 12.1 55.8 ± 14.0 <0.0001
Sex (male/female, %) 59.6/40.4 51.4/48.6 <0.0001
Body mass index (kg/m2) 23.9 ± 3.6 22.6 ± 3.2 <0.0001
Current or former smoker 
(%) 35.3 37.9 0.0021
Diabetes mellitus (%) 35.3 12.1 <0.0001
Dyslipidemia (%) 69.6 51.7 <0.0001
Chronic kidney disease (%) 32.4 14.0 <0.0001
Hyperuricemia (%) 23.6 11.1 <0.0001
Systolic blood pressure 
(mmHg) 144 ± 24 116 ± 12 <0.0001
Diastolic blood pressure 
(mmHg) 81 ± 14 70 ± 10 <0.0001
Quantitative data are means ± SD and were compared between subjects with hypertension and controls with the unpaired 
Student’s t test. Categorical data were compared between the two groups with Fisher’s exact test. Based on Bonferroni’s 
correction, a P value of <0.0050 (0.05/10) was considered statistically significant.
Table 4: Relation of SNPs to hypertension as determined by multivariable logistic regression analysis
SNP
Dominant Recessive Additive 1 Additive 2
P OR (95% CI) P OR (95% CI) P OR (95% CI) P OR 
(95% CI)
rs150854849 C/T (R179Q) 1.90 × 10-16 6.53 (3.79–12.41) ND 1.90 × 10-16 6.53 (3.79–12.41) ND
rs2867125 G/A 0.0058 0.88 (0.80–0.96) 0.4777 0.0076 0.88 (0.80–0.97) 0.4056
rs202069030 G/C (R51S) 1.01 × 10-15 0.15 (0.08–0.25) ND 1.01 × 10-15 0.15 (0.08–0.25) ND
rs139012426 G/C (S1242T) 7.12 × 10-11 0.24 (0.15–0.38) ND 7.12 × 10-11 0.24 (0.15–0.38) ND
rs75432131 G/A (H606Y) 0.0046 1.36 (1.10–1.69) 0.2511 0.0065 1.35 (1.09–1.67) 0.2473
rs12229654 T/G 1.13 × 10-6 0.83 (0.77–0.90) 0.0132 0.82 (0.70–0.96) 1.44 × 10-5 0.84 (0.78–0.91) 0.0014 0.77 
(0.65–0.90)
rs76974938 C/T (D67N) 5.14 × 10-5 0.69 (0.57–0.82) ND 5.14 × 10-5 0.69 (0.57–0.82) ND
rs201633733 A/G 0.0025 2.80 (1.43–5.73) ND 0.0025 2.80 (1.43–5.73) ND
rs12352313 A/G (N901S) 0.0086 0.89 (0.81–0.97) 0.0518 0.0240 0.90 (0.82–0.99) 0.0394 0.70 
(0.51–0.98)
Multivariable logistic regression analysis was performed with adjustment for age and sex. Based on Bonferroni’s correction, P values of <1.25 × 
10–4 (0.05/400) were considered statistically significant and are shown in bold. OR, odds ratio; CI, confidence interval; ND, not determined.
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Table 5: Relation of SNPs to systolic or diastolic blood pressure (BP)
SNP Systolic BP (mmHg) P Diastolic BP (mmHg) P
Associated with systolic and diastolic BP and hypertension
rs12229654 T/G TT TG GG TT TG GG
132 ± 24 130 ± 23 128 ± 24 1.16 × 10-10 77 ± 14 75 ± 13 75 ± 13 6.50 × 10-12
Associated with systolic and diastolic BP
rs671 G/A (E504K) GG GA AA GG GA AA
132 ± 24 130 ± 23 129 ± 24 2.32 × 10-11 77 ± 14 75 ± 13 75 ± 13 5.02 × 10-15
rs11066015 G/A GG GA AA GG GA AA
132 ± 24 130 ± 23 129 ± 24 3.87 × 10-11 77 ± 14 75 ± 13 75 ± 13 7.37 × 10-15
rs2074356 C/T CC CT TT CC CT TT
132 ± 24 130 ± 23 129 ± 24 9.57 × 10-10 77 ± 14 75 ± 13 74 ± 13 1.40 × 10-12
rs3782886 A/G AA AG GG AA AG GG
132 ± 24 130 ± 23 129 ± 24 2.38 × 10-9 77 ± 14 75 ± 13 75 ± 13 4.40 × 10-14
rs11066280 T/A TT TA AA TT TA AA
132 ± 24 130 ± 23 129 ± 24 4.71 × 10-9 77 ± 14 75 ± 13 75 ± 13 9.81 × 10-14
Associated with systolic BP
rs78010183 A/T (T1305S) AA AT AA AT
132 ± 24 120 ± 16 <1.0 × 10-23 76 ± 14 74 ± 12 0.0011
rs141569282 G/A (A117T) GG GA GG GA
134 ± 25 121 ± 17 <1.0 × 10-23 77 ± 14 74 ± 12 0.0002
rs200982668 G/A (E2501K) GG GA GG GA
131 ± 24 120 ± 16 2.50 × 10-22 76 ± 14 75 ± 12 0.0473
rs61734696 G/T (Q137K) GG GT GG GT
131 ± 24 119 ± 16 3.50 × 10-22 76 ± 14 75 ± 12 0.0303
rs200787930 C/T (E1095K) CC CT CC CT
131 ± 24 119 ± 16 6.50 × 10-22 76 ± 14 75 ± 12 0.0640
rs139537100 C/T (R24Q) CC CT CC CT
131 ± 24 120 ± 16 2.54 × 10-21 76 ± 14 75 ± 12 0.0449
rs199921354 C/T (R80Q) CC CT CC CT
131 ± 24 120 ± 16 4.06 × 10-21 76 ± 14 75 ± 12 0.0471
rs188378669 G/T (E31*) GG GT GG GT
131 ± 24 120 ± 16 1.40 × 10-20 76 ± 14 75 ± 12 0.0912
rs146092501 C/T (E1386K) CC CT CC CT
131 ± 24 120 ± 16 2.45 × 10-20 76 ± 14 75 ± 12 0.0565
rs146879198 G/A (R340*) GG GA GG GA
131 ± 24 120 ± 16 2.70 × 10-20 76 ± 14 75 ± 12 0.0982
(Continued )
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SNP Systolic BP (mmHg) P Diastolic BP (mmHg) P
rs115287176 G/A (R277W) GG GA GG GA
131 ± 24 120 ± 16 5.08 × 10-20 76 ± 14 75 ± 12 0.0941
rs192210727 G/T (R580I) GG GT TT GG GT TT
131 ± 24 120 ± 16 118 ± 10 8.83 × 10-19 76 ± 14 75 ± 12 70 ± 11 0.1403
rs199576535 G/A (V341I) GG GA GG GA
131 ± 24 120 ± 17 5.70 × 10-16 76 ± 14 75 ± 14 0.0243
rs147284320 C/T (V503I) CC CT CC CT
128 ± 21 120 ± 16 4.36 × 10-14 75 ± 12 75 ± 12 0.6346
rs201459911
G/A 
(A1115V)
GG GA GG GA
131 ± 24 143 ± 28 1.16 × 10-14 76 ± 14 76 ± 16 0.4868
rs199976159 G/A (G222S) GG GA GG GA
131 ± 24 149 ± 25 3.98 × 10-9 76 ± 14 73 ± 15 0.0627
rs2523638 G/A GG GA AA GG GA AA
130 ± 23 131 ± 24 133 ± 25 7.24 × 10-8 76 ± 13 76 ± 13 77 ± 14 0.0002
rs11191454 A/G AA AG GG AA AG GG
132 ± 24 130 ± 24 128 ± 22 1.43 × 10-7 77 ± 14 76 ± 13 75 ± 13 0.0032
rs12182351 T/C TT TC CC TT TC CC
130 ± 23 132 ± 25 132 ± 24 2.43 × 10-9 76 ± 13 77 ± 14 76 ± 14 0.0010
rs12413409 G/A GG GA AA GG GA AA
132 ± 24 130 ± 24 128 ± 22 2.03 × 10-7 77 ± 14 76 ± 14 75 ± 13 0.0029
rs144936999 G/C (A332P) GG GC GG GC
131 ± 24 154 ± 32 4.16 × 10-8 76 ± 14 76 ± 15 0.9989
rs404890 G/T GG GT TT GG GT TT
130 ± 23 132 ± 25 132 ± 24 7.91 × 10-9 76 ± 13 77 ± 14 76 ± 14 0.0018
rs130075 C/T (R102Q) CC CT TT CC CT TT
132 ± 24 129 ± 23 129 ± 22 8.48 × 10-8 76 ± 14 76 ± 13 75 ± 14 0.0152
rs11191580 T/C TT TC CC TT TC CC
132 ± 24 130 ± 24 128 ± 22 4.44 × 10-7 77 ± 14 76 ± 13 75 ± 13 0.0027
rs1058026 T/G TT TG GG TT TG GG
132 ± 24 130 ± 24 129 ± 22 6.18 × 10-7 77 ± 14 76 ± 13 76 ± 13 0.1202
rs11191548 T/C TT TC CC TT TC CC
132 ± 24 130 ± 24 128 ± 22 6.26 × 10-7 77 ± 14 76 ± 13 75 ± 13 0.0033
rs2270191 C/T (V5M) CC CT TT CC CT TT
132 ± 24 129 ± 23 129 ± 22 4.19 × 10-7 76 ± 14 76 ± 13 75 ± 14 0.0490
(Continued )
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SNP Systolic BP (mmHg) P Diastolic BP (mmHg) P
rs117951780 C/T (S453N) CC CT TT CC CT TT
132 ± 24 129 ± 23 129 ± 22 5.95 × 10-7 76 ± 14 76 ± 13 75 ± 14 0.0461
rs2270190 T/C TT TC CC TT TC CC
132 ± 24 129 ± 23 129 ± 22 5.73 × 10-7 76 ± 14 76 ± 13 76 ± 14 0.0360
rs17115100 G/T GG GT TT GG GT TT
132 ± 24 131 ± 24 128 ± 21 3.37 × 10-7 77 ± 14 76 ± 14 75 ± 13 0.0101
rs72655343 C/A CC CA CC CA
131 ± 24 149 ± 30 4.24 × 10-7 76 ± 14 77 ± 17 0.7231
rs1063646 C/T (P133L) CC CT TT CC CT TT
132 ± 24 129 ± 23 130 ± 23 6.24 × 10-7 76 ± 14 76 ± 13 76 ± 14 0.0473
rs9263739 C/T CC CT TT CC CT TT
132 ± 24 129 ± 23 130 ± 23 6.24 × 10-7 76 ± 14 76 ± 13 76 ± 14 0.0473
rs1004467 T/C TT TC CC TT TC CC
132 ± 24 131 ± 24 128 ± 21 2.28 × 10-6 77 ± 14 76 ± 14 75 ± 13 0.0208
rs139421991 G/A (R320Q) GG GA GG GA
131 ± 24 143 ± 28 6.74 × 10-7 76 ± 14 79 ± 18 0.0280
rs7757012 T/C TT TC CC TT TC CC
132 ± 24 129 ± 23 130 ± 23 1.02 × 10-6 76 ± 14 76 ± 13 76 ± 13 0.0526
rs142979264 C/T CC CT TT CC CT TT
132 ± 24 129 ± 23 128 ± 21 3.71 × 10-6 76 ± 14 76 ± 13 76 ± 13 0.0756
rs10849915 T/C TT TC CC TT TC CC
132 ± 24 130 ± 24 129 ± 23 7.27 × 10-6 77 ± 14 76 ± 13 75 ± 13 7.60 × 10-5
Associated with diastolic BP
rs7969300 T/C (N248S) TT TC CC TT TC CC
130 ± 24 131 ± 24 133 ± 25 0.0039 76 ± 14 76 ± 14 78 ± 14 4.59 × 10-8
rs12231744 C/T (R876K) CC CT TT CC CT TT
131 ± 24 131 ± 24 133 ± 25 0.0145 76 ± 14 76 ± 14 78 ± 14 1.44 × 10-7
Associated with hypertension
rs150854849 C/T (R179Q) CC CT CC CT
131 ± 25 133 ± 23 0.5574 76 ± 14 76 ± 10 0.7538
rs202069030 G/C (R51S) GG GC GG GC
131 ± 24 131 ± 24 0.9913 76 ± 14 75 ± 10 0.6866
rs139012426 G/C (S1242T) GG GC GG GC
131 ± 24 138 ± 26 0.1728 76 ± 14 77 ± 9 0.8428
rs76974938 C/T (D67N) CC CT CC CT
131 ±25 132 ±19 0.1772 76 ± 14 75 ± 11 0.0291
Data are compared among genotypes by one-way analysis of variance. Based on Bonferroni’s correction, P values of 
<0.0005 (0.05/100) were considered statistically significant and are shown in bold.
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DISCUSSION
We have now shown that rs12229654 at 12q24.1 
was significantly associated with both systolic and 
diastolic BP as well as with hypertension and that rs671 
of ALDH2, rs11066015 of ACAD10, rs2074356 and 
rs11066280 of HECTD4, and rs3782886 of BRAP were 
significantly associated with both systolic and diastolic BP. 
Among these loci, ALDH2 and HECTD4 were identified 
as susceptibility loci for BP in a previous GWAS [10]. 
The remaining SNPs at three loci (12q24.1, ACAD10, and 
BRAP) are newly identified as genetic determinants of 
systolic and diastolic BP in Japanese. We also uncovered 
an additional 38 and two SNPs that were associated with 
systolic or diastolic BP, respectively, as well as four SNPs 
associated with hypertension.
The six SNPs (rs12229654, rs671, rs11066015, 
rs2074356, rs3782886, rs11066280) significantly 
associated with BP are clustered at 12q24.12-q24.13 
and are in linkage disequilibrium with each other. The 
SNP rs12229654 at 12q24.1 was previously shown to 
be associated with body mass index [15] and metabolic 
syndrome [16], with obesity and metabolic syndrome 
both being risk factors for elevated BP. The aldehyde 
dehydrogenase 2 family gene (ALDH2) is located at 
12q24.12 (NCBI Gene, https://www.ncbi.nlm.nih.gov/
gene) and is expressed in various organs and tissues, 
especially the liver (The Human Protein Atlas, http://
www.proteinatlas.org). ALDH2 catalyze the second step 
of the major oxidative pathway of alcohol metabolism 
(NCBI Gene). ALDH2 was previously shown to be 
associated with BP and hypertension [8, 10] The acyl-
CoA dehydrogenase family member 10 gene (ACAD10) 
is located at 12q24.12 (NCBI Gene), is ubiquitously 
expressed (The Human Protein Atlas), and activates 
the β-oxidation of fatty acids in mitochondria (NCBI 
Gene). ACAD10 has not previously been associated 
with BP or hypertension, although rs11066015 of this 
gene was shown to be related to coronary artery disease 
[17]. The HECT domain E3 ubiquitin protein ligase 4 
gene (HECTD4) is located at 12q24.13 (NCBI Gene) 
and is broadly expressed (The Human Protein Atlas). 
E3 ligases accept ubiquitin from an E2 ubiquitin-
conjugating enzyme in the form of a thioester and then 
directly transfer the ubiquitin moiety to target substrates 
[Universal Protein Resource, http://www.uniprot.
org]. HECTD4 was previously found to be associated 
with systolic and diastolic BP [10, 18]. The BRCA1 
associated protein gene (BRAP) is located at 12q24.12 
(NCBI Gene) and is ubiquitously expressed, with its 
expression level being especially high in the testis 
(The Human Protein Atlas). BRAP has not previously 
been associated with BP or hypertension, although it 
was found to be a susceptibility locus for myocardial 
infarction [19].
In recent large-scale GWASs, the MAFs of BP-
associated SNPs were 5% to 50% (mean, 29.8%) and their 
effect sizes for systolic or diastolic BP were 0.07 to 1.13 
mmHg (mean, 0.46 mmHg) and 0.06 to 0.6 mmHg (mean, 
0.28 mmHg), respectively [20]. In our study, the MAFs of 
the six SNPs (rs12229654, rs671, rs11066015, rs2074356, 
rs3782886, rs11066280) associated with both systolic and 
diastolic BP were 22.5% to 29.3% and the differences 
in systolic or diastolic BP among genotypes were 3 to 4 
mmHg and 2 to 3 mmHg, respectively. These SNPs were 
thus common variants with moderate effect sizes. We also 
detected an additional 38 and two SNPs associated with 
systolic or diastolic BP, respectively. Nineteen of these 
38 SNPs associated with systolic BP had a MAF of 0.1% 
to 2.0% and the corresponding differences in systolic BP 
among (or between) genotypes were 11 to 23 mmHg; 
these SNPs were thus low-frequency or rare variants with 
large effect sizes. The remaining 19 SNPs were common 
variants (MAF, 11.8% to 43.1%) with differences in 
systolic BP among (or between) genotypes being 2 to 4 
mmHg. The additional two SNPs associated with diastolic 
BP were common variants (MAF, 35.1% and 38.8%), with 
the differences in diastolic BP among genotypes being 2 
mmHg.
There were several limitations to the present 
study: (1) Given that the results were not replicated, they 
will require validation in other independent populations 
or in other ethnic groups. (2) Given that subjects were 
recruited by different methods, hypertension may be 
a more reliable phenotype compared with BP in the 
present study. Therefore the relation of SNPs to systolic 
and diastolic BP should be interpreted carefully. (3) 
Given that the prevalence of hypertension was higher 
in the subjects recruited from the hospitals than in those 
from the general population, selection bias could not 
be excluded. (4) It is possible that the SNPs identified 
in the present study are in linkage disequilibrium with 
other polymorphisms in nearby genes that are actually 
responsible for the regulation of BP or the development 
of hypertension. (5) Four SNPs identified as 
susceptibility loci for hypertension were not associated 
with systolic or diastolic BP, possibly as a result of the 
effect of antihypertensive treatment. (6) The functional 
relevance of the identified SNPs to the pathogenesis of 
hypertension remains to be determined.
In conclusion, we have identified six SNPs 
(rs12229654 at 12q24.1, rs671 of ALDH2, rs11066015 of 
ACAD10, rs2074356 and rs11066280 of HECTD4, and 
rs3782886 of BRAP) as genetic determinants of BP. Among 
these loci, ALDH2 and HECTD4 were previously associated 
with BP [10]. The remaining SNPs at three loci (12q24.1, 
ACAD10, and BRAP) are newly identified as determinants of 
BP in Japanese. Determination of genotypes for these SNPs 
may prove informative for assessment of the genetic risk for 
hypertension in Japanese.
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MATERIALS AND METHODS
Study subjects
A total of 14,678 subjects (8215 patients with 
hypertension and 6463 control individuals) was examined. 
The subjects were recruited from individuals as described 
previously [21].
The subjects with hypertension either had a systolic 
BP of ≥140 mmHg or diastolic BP of ≥90 mmHg (or both) 
or had taken antihypertensive medication. Individuals with 
severe valvular heart disease, congenital malformations 
of the heart or vessels, renal or endocrinologic diseases 
that cause secondary hypertension, or drug-induced 
hypertension were excluded from the study. The control 
individuals had a systolic BP of <140 mmHg and diastolic 
BP of <90 mmHg as well as no history of hypertension 
or of taking antihypertensive medication. Autopsy cases 
were excluded from controls. BP was measured at least 
twice with subjects having first rested in the sitting 
position for >5 min; the measurements were taken by a 
skilled physician or nurse according to the guidelines of 
the American Heart Association [22].
EWASs for systolic or diastolic BP and for 
hypertension
Methods for collection and extraction of genomic 
DNA samples were described previously [21]. The EWASs 
were performed with the use of a HumanExome-12 v1.1 
or v1.2 DNA Analysis BeadChip or Infinium Exome-24 
v1.0 BeadChip (Illumina, San Diego, CA, USA). Exome 
array contains ~244,000 SNPs including common, low 
frequency, and rare variants located at whole exons. 
The GWAS makes use of high-throughput genotyping 
technologies that include up to 4.5 million markers for 
SNPs and copy number variations to examine their relation 
to clinical conditions or traits. The EWAS is a focus 
genotyping method that differs from the GWAS [23]. 
Detailed information of the exome arrays and methods of 
quality control were described previously [21]. A total of 
41,843 SNPs passed quality control and was subjected to 
analysis.
Statistical analysis
For analysis of characteristics of the study subjects, 
quantitative data were compared between patients with 
hypertension and controls with the unpaired Student’s t 
test. Categorical data were compared between the two 
groups with Fisher’s exact test. Allele frequencies were 
estimated by the gene counting method, and Fisher’s 
exact test was applied to identify departure from Hardy-
Weinberg equilibrium. The relation of genotype of each 
SNP to systolic or diastolic BP in the EWAS was analyzed 
with a linear regression model. Allele frequencies of 
SNPs were compared between subjects with hypertension 
and controls in the EWAS with Fisher’s exact test. To 
compensate for multiple comparisons of genotypes 
with hypertension, we applied Bonferroni’s correction 
for statistical significance of association. Given that 
41,843 SNPs were analyzed, the significance level was 
set at P < 1.19 × 10–6 (0.05/41,843) for each EWAS. 
Quantile-quantile plots for P values of genotypes or allele 
frequencies in the EWASs for systolic or diastolic BP or 
for hypertension are shown in Supplementary Figure 2. 
The inflation factor (λ) was 0.95 for systolic BP, 1.05 for 
diastolic BP, and 1.11 for hypertension. Multivariable 
logistic regression analysis was performed with 
hypertension as a dependent variable and independent 
variables including age, sex (0, woman; 1, man), and 
genotype of each SNP. A detailed method of analysis was 
described previously [21]. The relation of genotypes of 
isolated SNPs to systolic or diastolic BP was examined 
with one-way ANOVA. Bonferron’s correction was also 
applied to other analyses as indicated. Statistical tests were 
performed with JMP Genomics version 6.0 software (SAS 
Institute, Cary, NC, USA).
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